NICE didn't accept a bigger discount on Zolgensma between 2021 and 2023. It accepted a longer time horizon, and that Long-Term Value Framework decision is the actual UK SMA pricing lever.
NICE rejected Zolgensma under its Highly Specialised Technologies (HST) route in 2021 (HST15), when the cost per QALY at WAC (approximately £1.8 million) exceeded £200,000 without an adequate discount. Novartis did not simply cut price to win reversal. It returned in 2022 with a revised Patient Access Scheme and NICE applied its Long-Term Value Framework (LTVF), a methodology that extends cost-effectiveness modelling beyond the standard 30-year horizon to reflect gene therapy's potentially durable effect. HST24 (2023) accepted the case under a Managed Access Agreement requiring two years of real-world outcome data across 6 NHS gene therapy centres. The mechanism that flipped the decision was the modelling horizon, not the discount depth, and that is the precedent any second SMA gene therapy submission has to engage with directly.
Priced against that reversal, an estimated £1.2-1.6 million PAS net cost for a newborn-screening-identified infant beats an estimated £4.5-7.5 million lifetime cost of chronic therapy (nusinersen or risdiplam at roughly £150,000-250,000 a year over 30-plus years). Nusinersen alone runs £150,000-250,000 a year in maintenance, with a £500,000-700,000 loading year, and combined NHS chronic SMA spend across nusinersen and risdiplam is estimated at £45-75 million annually. Any new UK entrant, gene therapy or chronic, has to price against this exact break-even logic: NICE will not reward parity pricing once an incumbent has already cleared the QALY bar under LTVF, so the pricing strategy question is which lever, discount, horizon, or subgroup, a new submission pulls.
UK SMA pricing — the NICE LTVF mechanism that flipped Zolgensma's appraisal
| Agent | NICE Route | Estimated NHS Cost | Mechanism |
|---|---|---|---|
| Zolgensma (onasemnogene abeparvovec) | HST15 rejected 2021; HST24 accepted 2023 | Est. £1.2-1.6M PAS net cost, one-time | Long-Term Value Framework extended modelling horizon |
| Spinraza (nusinersen) | TA588 (2019), with PAS | £150,000-250,000/yr (loading yr £500,000-700,000) | Standard TA cost-effectiveness |
| Evrysdi (risdiplam) | TA755 (2022), with PAS | Est. £100,000-200,000/yr | Standard TA cost-effectiveness |
Sources: NICE HST24 (2023) and HST15 (2021) documentation; NICE TA588 (nusinersen, 2019); NICE TA755 (risdiplam, 2022); NICE Long-Term Value Framework methodology; NHS England SMA commissioning budget.
What this model answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- HST15 (2021) rejection basis vs HST24 (2023) LTVF methodology
- the modelling-horizon mechanism
- what a second gene therapy submission needs to replicate
Delivers
- NHS break-even model
- nusinersen/risdiplam annual cost baseline
- the pricing ceiling this sets for any new SMA agent
Delivers
- NICE's post-LTVF evaluation posture
- discount-vs-horizon-vs-subgroup lever analysis
- the Managed Access Agreement precedent for data-conditional pricing
Custom model delivered in 72 hours.
Commission This ModelWhat's inside
- Why NICE's Long-Term Value Framework, not the PAS discount, decided Zolgensma's price
- Pressure-tested against the £1.2-1.6M vs £4.5-7.5M break-even before the rest of the model is built out
- How the Long-Term Value Framework extended the modelling horizon to flip HST15 into HST24
- Where nusinersen and risdiplam already price against the standard NICE ceiling
- What specifically changed in NICE's evaluation between 2021 and 2023
- The Managed Access Agreement's 2-year real-world data requirement
- Nusinersen TA588 and risdiplam TA755 PAS cost as the comparator set
- What the analogue class supports for a new entrant's defensible NICE case
- NICE's own break-even modelling between one-time and lifetime cost
- Where the evidence base is strong enough to support a premium
- The WAC, PAS, and MAA components decomposed line by line
- The discount depth already observed at HST24
- Sequencing recommendation for a gene therapy vs chronic entrant
- Conservative, base, and aggressive revenue scenarios tied to NHS gene-therapy centre capacity
- The open pricing questions your team must close before a UK NICE submission is locked
- Structured for an internal pricing committee session
Included with every brief
How AXLRx builds this model
Prepared by MoatRx analysts.
Every AXLRx pricing model is built from primary NICE and NHS sources (HST/TA appraisal documentation, LTVF methodology papers, NHS commissioning budget data), not secondary summaries. Findings are independently verified before inclusion.
SMA UK pricing sources: NICE HST24 (2023) and HST15 (2021) documentation, NICE TA588 (nusinersen, 2019), NICE TA755 (risdiplam, 2022), the NICE Long-Term Value Framework methodology, and NHS England SMA commissioning budget analysis.
- HST15 rejection and HST24 reversal verified against NICE Highly Specialised Technologies evaluation documentation
- PAS net cost estimate and lifetime chronic-cost comparison verified against NICE HST24 cost-effectiveness model documentation
- Nusinersen and risdiplam PAS pricing verified against NICE TA588 and TA755 documentation and NHS England SMA commissioning budget analysis
Frequently asked questions
Commission this model
AXLRx delivers UK SMA pricing strategy models built for market access and pricing teams navigating NICE's Long-Term Value Framework and PAS/MAA precedent. Custom model in 72 hours.
Specify your indication, market basket, and comparator scope.
AXLRx analyst confirms pricing mechanism assumptions and WTP threshold before building.
Research-verified pricing model in 72 hours with optional analyst readout.